Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Lambrechts, Yentl
Hatse, Sigrid
Kenis, Cindy
Decoster, Lore
de Azambuja, Evandro
Jerusalem, Guy
Neven, Patrick
Dal Lago, Lissandra
Denys, Hannelore
Vuylsteke, Peter
Cornelis, Frank
Punie, Kevin
Floris, Giuseppe
Desmedt, Christine
Laenen, Annouschka
Ponde, Noam
Wildiers, Hans
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-29
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2-metastatic breast cancer
    Goyal, Ravi K.
    Carter, Gebra Cuyun
    Nagar, Saurabh P.
    Smyth, Emily N.
    Price, Gregory L.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1699 - 1710
  • [22] Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib
    Balu, Sanjeev
    Burne, Rebecca
    Guerin, Annie
    Bungay, Rebecca
    Paul, Mary Lisha
    Sin, Roxana
    CANCER RESEARCH, 2021, 81 (04)
  • [23] Treatment of pre- and postmenopausal Women with HR+/HER2-metastatic Breast Cancer Ribociclib receives high AGO Recommendation Level
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [24] Abemaciclib in HR+/Her2-metastatic breast cancer patients after previous progression on palbociclib or ribociclib: Clinical experience in a tertiary hospital in Madrid, Spain
    De Luna Aguilar, A.
    Moreno Anton, F.
    Benitez Fuentes, J. D.
    Ortega Anselmi, J.
    Olalla Inoa, J.
    Flores Navarro, P.
    Garcia Saenz, J. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S219 - S220
  • [25] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [26] Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2-metastatic breast cancer in US real-world clinical practice
    DeMichele, Angela
    Cristofanilli, Massimo
    Brufsky, Adam
    Liu, Xianchen
    Mardekian, Jack
    McRoy, Lynn
    Layman, Rachel M.
    Emir, Birol
    Torres, Mylin A.
    Rugo, Hope S.
    Finn, Richard S.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [27] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [28] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2-Metastatic Breast Cancer
    Brufsky, Adam M.
    Sandin, Rickard
    Stergiopoulos, Stella
    Chen, Connie
    Karanth, Siddharth
    Li, Benjamin
    Esterberg, Elizabeth
    Makari, Doris
    Candrilli, Sean D.
    Goyal, Ravi K.
    Rugo, Hope S.
    CANCER MEDICINE, 2025, 14 (07):
  • [30] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
12345